Skip to Content
MDPIMDPI
JCMJournal of Clinical Medicine
PDF
  • Editorial
  • Open Access

9 January 2022

New Horizons for Personalised Treatment in Gastroesophageal Cancer

and
1
Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy
2
PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, 41121 Modena, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med.2022, 11(2), 311;https://doi.org/10.3390/jcm11020311
This article belongs to the Special Issue Novel Therapeutic Approaches for Gastroesophageal Cancer
Version Notes
Order Reprints
Gastric and gastroesophageal junction adenocarcinoma (GEA) is still responsible for a huge health burden worldwide, being the second most common cause of cancer-related death globally [1]. Even though GEA is not ranked in the top-five malignancy in developed countries, its incidence is increasing among younger individuals, particularly at the proximal anatomical subsite [2].
The recent years have witnessed unprecedented advances in the field of surgical techniques, loco-regional procedures and systemic therapies that have enabled incremental yet steady improvements in patients’ outcomes and have made the multidisciplinary approach an unavoidable need in GEA. In parallel, the availability of high-throughput technologies has deepened the molecular understanding of the disease, unveiling considerable biological heterogeneity and vulnerabilities.
In potentially resectable GEA, particularly in Western countries, taxane-based triplet chemotherapy has been established as the new reference perioperative regimen, which provides a 10% increase in curability in the growing proportion of patients who are given upfront systemic treatment versus the previous anthracyclines-based standard of care [3]. In this setting, the MSI testing at diagnosis is increasingly performing: MSI-h tumours had a better prognosis with surgery alone and a recent meta-analysis reported detrimental survival with platinum-fluoropyrimidine based perioperative chemotherapy [4], suggesting in some centres, an upfront surgery approach, while others are investigating chemo-free immunotherapy-based approaches, such as that pursued in the currently ongoing INFINITY trial [5].
In metastatic GEA, after years of stagnation and a plateau for standard cytotoxic polychemotherapy, the molecular segmentation that emerged from the TCGA project has provided a roadmap for personalised treatments [6]. In HER2-negative GEA with PD-L1 CPS ≥ 5, the addition of the anti-PD1 nivolumab to first-line chemotherapy provided practice-changing results in the phase III Check-Mate-649 trial [7]. There is now convincing evidence also for GEA that MSI-h metastatic tumours derived greater benefit from immune checkpoint blockade than standard therapy [8], while this finding needs prospective confirmation for the subset of TMB-H and EBV-positive tumours.
Among the molecular subgroup of HER2-positive GEA, a renewed enthusiasm surrounds novel targeted agents of which trastuzumab deruxtecan is the most promising at this point [9]. This antibody–drug conjugate against HER2 produced a remarkable improvement in response rate (51% vs. 14%) and overall survival (12.5 vs. 8.4 months) when compared to chemotherapy in heavily pretreated patients.
Regarding novel tools for precision medicine, blood-based ctDNA analysis (referred to as liquid biopsy) is showing potential transformative applications in GEA, including the detection of minimal residual disease after curative treatment, the capture of resistance mechanisms and the identification of new targets in GEA [10,11,12]. Moreover, advances in preclinical cancer models have led to the establishment of patient-derived organoids as rapid, reliable and cost-effective tools to run high-throughput 3D drug screening, study drug resistance and, more interestingly, model treatment response to systemic therapies [13].
This Special Issue aims to discuss open questions, highlight major innovations and depict future perspectives in the multidisciplinary management of gastroesophageal cancer, bridging together major specialties committed to the personalisation and improvement of GEA patient care.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimated Cancer Incidence, Mortality and Prevalence Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  2. Anderson, W.F.; Camargo, M.C.; Fraumeni, J.F., Jr.; Correa, P.; Rosenberg, P.S.; Rabkin, C.S. Age-specific trends in incidence of non-cardia gastric cancer in US adults. JAMA 2010, 303, 1723–1728. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Al-Batran, S.-E.; Homann, N.; Pauligk, C.; Goetze, T.O.; Meiler, J.; Kasper, S.; Kopp, H.-G.; Mayer, F.; Haag, G.M.; Luley, K.; et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019, 393, 1948–1957. [Google Scholar] [CrossRef] [PubMed]
  4. Pietrantonio, F.; Miceli, R.; Raimondi, A.; Kim, Y.W.; Kang, W.K.; Langley, R.E.; Choi, Y.Y.; Kim, K.-M.; Nankivell, M.G.; Morano, F.; et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability as a Biomarker in Gastric Cancer. J. Clin. Oncol. 2019, 37, 3392–3400. [Google Scholar] [CrossRef] [PubMed]
  5. Raimondi, A.; Palermo, F.; Prisciandaro, M.; Aglietta, M.; Antonuzzo, L.; Aprile, G.; Berardi, R.; Cardellino, G.G.; de Manzoni, G.; de Vita, F.; et al. TremelImumab and Durvalumab Combination for the Non-OperatIve Man-agement (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers 2021, 13, 2839. [Google Scholar] [CrossRef] [PubMed]
  6. Salati, M.; Orsi, G.; Smyth, E.; Beretta, G.; de Vita, F.; di Bartolomeo, M.; Fanotto, V.; Lonardi, S.; Morano, F.; Pietrantonio, F.; et al. Gastric cancer: Translating novels concepts into clinical practice. Cancer Treat. Rev. 2019, 79, 101889. [Google Scholar] [CrossRef] [PubMed]
  7. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A.C.; et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021, 3, 27–40. [Google Scholar] [CrossRef]
  8. Pietrantonio, F.; Randon, G.; di Bartolomeo, M.; Luciani, A.; Chao, J.; Smyth, E.; Petrelli, F. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: A meta-analysis of randomized clinical trials. ESMO Open 2021, 6, 100036. [Google Scholar] [CrossRef] [PubMed]
  9. Shitara, K.; Bang, Y.-J.; Iwasa, S.; Sugimoto, N.; Ryu, M.-H.; Sakai, D.; Chung, H.-C.; Kawakami, H.; Yabusaki, H.; Lee, J.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N. Engl. J. Med. 2020, 382, 2419–2430. [Google Scholar] [CrossRef] [PubMed]
  10. Leal, A.; van Grieken, N.C.T.; Palsgrove, D.N.; Phallen, J.; Medina, J.E.; Hruban, C.; Broeckaert, M.A.M.; Anagnostou, V.; Adleff, V.; Bruhm, D.C.; et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat. Commun. 2020, 11, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Maron, S.B.; Chase, L.M.; Lomnicki, S.; Kochanny, S.; Moore, K.L.; Joshi, S.S.; Landron, S.; Johnson, J.; Kiedrowski, L.A.; Nagy, R.J.; et al. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin. Cancer Res. 2019, 25, 7098–7112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Salati, M.; Venetis, K.; Fassan, M.; Malapelle, U.; Pagni, F.; Sajjadi, E.; Fusco, N.; Ghidini, M. ctDNA analysis in the personalized clinical management of gastroesophageal adeno-carcinoma: Turning hope into reality. Future Oncol. 2021, 17, 4607–4618. [Google Scholar] [CrossRef] [PubMed]
  13. Seidlitz, T.; Merker, S.R.; Rothe, A.; Zakrzewski, F.; von Neubeck, C.; Grützmann, K.; Sommer, U.; Schweitzer, C.; Schölch, S.; Uhlemann, H.; et al. Human gastric cancer modelling using organoids. Gut 2019, 6, 207–217. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Post-Ureteroscopy Infections Are Linked to Pre-Operative Stent Dwell Time over Two Months: Outcomes of Three European Endourology Centres
Previous
C-Reactive Protein Monitoring and Clinical Presentation of Fever as Predictive Factors of Prolonged Febrile Neutropenia and Blood Culture Positivity after Autologous Hematopoietic Stem Cell Transplantation—Single-Center Real-Life Experience
Next